Prostate-specific polynucleotide compositions

Details Prostate-specific polynucleotide compositions Prostate-specific polynucleotide compositions

2006-04-25

2006-04-25

Brusca, John (Department: 1631)

Chemistry: molecular biology and microbiology

Vector, per se

C435S006120, C435S252300, C435S325000, C536S023100, C536S024100

Reexamination Certificate

active

07033827

ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

REFERENCES:
patent: 5786148 (1998-07-01), Bandman et al.
patent: 6130043 (2000-10-01), Billing-Medel et al.
patent: 6620922 (2003-09-01), Xu et al.
patent: 317 141 (1989-05-01), None
patent: 652 014 (1995-05-01), None
patent: WO 93/14755 (1993-08-01), None
patent: WO 93/25224 (1993-12-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 95/04548 (1995-02-01), None
patent: WO 95/14772 (1995-06-01), None
patent: WO 95/30758 (1995-11-01), None
patent: WO 96/21671 (1996-07-01), None
patent: WO 97/33909 (1997-09-01), None
patent: WO 98/12302 (1998-03-01), None
patent: WO 98/17687 (1998-04-01), None
patent: WO 98/20117 (1998-05-01), None
patent: WO 98/31799 (1998-07-01), None
patent: WO 98/37039 (1998-08-01), None
patent: WO 98/37093 (1998-08-01), None
patent: WO 98/37418 (1998-08-01), None
patent: WO 98/38310 (1998-09-01), None
patent: WO 98/39446 (1998-09-01), None
patent: WO 98/45435 (1998-10-01), None
patent: WO 98/50567 (1998-11-01), None
patent: WO 99/06548 (1999-02-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/06552 (1999-02-01), None
patent: WO 99/25825 (1999-05-01), None
patent: WO 99/31236 (1999-06-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 01/25272 (2001-04-01), None
patent: WO 01/34802 (2001-05-01), None
patent: WO 01/51633 (2001-07-01), None
Aspinall, J.O. et al., “Differential Expression of Apolipoprotein-D and Prostate Specific Antigen in Benign and Malignant Prostate Tissues,”Journal of Urology 154: 622-628, Aug. 1996.
Fannon, M.R., “Gene expression in normal and disease states—identification of therapeutic targets,”Trends in Biotechnology 14: 294-298, Aug. 1996.
Garde, S.V. et al., “Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP),”Cancer Letters 78: 11-17, 1994.
GenBank Database, Accession No. AA112574, May 29, 2003.
Murphy, G. et al., “Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients,”Anticancer Research 15: 1473-1480, 1995.
Ahn and Kunkel, “The structural and functional diversity of dystrophin,”Nature Genetics 3: 283-291, Apr., 1993.
Alexeyev et al., “Improved antibiotic-resistance gene cassettes and omega elements forEscherichia colivector construction and in vitro deletion/insertion mutagenesis,”Gene 160:63-67, 1995.
Berthon et al., “Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43,”Am. J. Hum. Genet. 62(6):1416-1424, Jun. 1998.
Blok et al., “Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR,”The Prostate 26:213-224, 1995.
Busselmakers et al., Genbank Accession No. AF103907, Aug. 14, 2000.
Busselmakers et al., Genbank Accession No. AF103908, Aug. 14, 2000.
Cawthon et al., “cDNA sequence and genomic structure of EVI2B, a gene lying within an intron of the neurofibromatosis type 1 gene,”Genomics 9:446-460, 1991.
Chu et al., “CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity,”J. Exp. Med. 186(10): 1623-1631, Nov. 17, 1997.
Coleman et al.,Fundamental Immunology, Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
Database EMBL Accesion No. AA453562, Jun. 11, 1997, Hillier et al., “Homo sapiens cDNA clone 788180.”.
Derwent Geneseq Database, Accession No. V58522, Dec. 8, 1998.
Derwent Geneseq Database, Accession No. V61287, Jan. 6, 1999.
Duerst and Noes. “Nucleic acid characteristic of late or early passage cells immortalized by papilloma virus-and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions,” Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent DE 19649207 C1.
El-Shirbiny, Prostatic Specific Antigen,Advances In Clinical Chemistry 31:99-133, 1994.
Ezzell, C., “Cancer vaccines: an idea whose time has come?”The Journal of NIH Research 7:46-49, Jan. 1995.
GenBank Accession No. AF047020, Feb. 1, 1999.
Hara et al., “Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8α in a mast cell-derived interleukin-4-dependent cell line,”Blood 84(1):189-199, Jul. 1, 1994.
Harris et al., “Polycystic Kidney Disease 1: identification and analysis of the primary defect,”J. Am. Soc. of Nephrol. 6:1125-1133, 1995.
Hillier et al., Genbank Accession No. AA100799, Dec. 23, 1997.
Hillier et al., Genbank Accession No. R20590, Apr. 18, 1995.
Hudson, T., Genbank Accession No. G22461, May 31, 1996.
Kroger, B. “New serine protease form human prostate, useful for identifying specific inhibitors, antibodies and probes,” Derwent World Patent Index, Accession No. 99-432218, 1999. See also European Patent EP 936 270 A2.
Lalvani et al., “Rapid effector function in CD8+memory cells,”J. Exp. Med. 186(6):859-865, Sep. 15, 1997.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, Sep. 5, 1997.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, Aug. 11, 1997.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, Oct. 31, 1997.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA653016, Nov. 25, 1997.
Nelson et al., Genbank Accession No. NP—004908, Mar. 18, 2000.
Robson et al., “Indentification of prostatic adrogen regulated genes using the differential display technique,”Proceeding of the American Association for Cancer Research Meeting 86, 36: p. 266, Abstract No. 1589,1995.
Schena et al., “Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes,”Proc. Natl. Acad. Sci. USA 93(19):10614-10619, Sep. 17, 1996.
Schmidt-Wolf et al., “Activated T cells and cytokine-induced CD3+CD56+killer cells,”Annals of Hematology 74:51-56, 1997.
Sherman et al., “Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8,”Science 258(5083):815-818, Oct. 30, 1992.
Short et al., “λ ZAP: a bacteriophage λ expression vector with in vivo excision properties,”Nucleic Acids Research 16(15):7583-7600, 1988.
Sjögren, H., “Therapeutic Immunization Against Cancer Antigens Using Genetically Engineered Cells,”Immunotechnology 3: 161-172, 1997.
Smith et al., “Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search,”Science 274(5291), 1371-1374, Nov. 22, 1996.
Theobald, et al., “Targeting p53 as a general tumor antigen,”Proc. Natl. Sci. USA 92(25):11993-11997, Dec. 5, 1995.
Tusnady and Simon, “Principles governing amino acid compositions of integral membrane proteins: application to topology prediction,”J. Mol. Biol. 283(2):489-506, Oct. 23, 1998.
Van Tsai et al., “In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells,”Critical Reviews in Immunology 18:65-75, 1998.
Vasmatzis et al., “Discovery of three genes specifically expressed in human pros

Affiliated with

Also associated with

Rating

Prostate-specific polynucleotide compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prostate-specific polynucleotide compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostate-specific polynucleotide compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3576564